Skip to Content

Novartis AG ADR

NVS: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$137.00CdsrDwjqdftk

Novartis Holds a Wide Portfolio of Drugs That Support Steady Cash Flows

Business Strategy and Outlook

With strong positions in multiple key therapeutic areas, Novartis is well positioned for steady long-term growth. Strong intellectual property supporting multibillion-dollar products, combined with an abundance of late-pipeline products, creates a wide economic moat. While patent losses on anemia drug Exjade and cancer drug Afinitor will weigh on near-term growth, a strong portfolio of drugs along with a robust pipeline should ensure steady long-term growth.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of NVS so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center